Kitmox-LD Ophthalmic Suspension is a combination medication containing Loteprednol etabonate 0.5% w/v, a corticosteroid, and Moxifloxacin 0.5% w/v, a fluoroquinolone antibiotic. This formulation is indicated for the treatment of ocular inflammatory conditions where bacterial infection or risk of infection is present, such as postoperative inflammation following cataract surgery or other ocular surgeries. Loteprednol etabonate exerts potent anti-inflammatory effects by inhibiting multiple inflammatory mediators, thereby reducing swelling, redness, and discomfort. Moxifloxacin provides broad-spectrum antibacterial activity against gram-positive and gram-negative pathogens by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial replication. The suspension is designed for topical ophthalmic use, ensuring targeted delivery with minimal systemic absorption. Kitmox-LD is typically administered as one or two drops into the affected eye(s) four times daily or as directed by a healthcare professional. Caution is advised in patients with known hypersensitivity to corticosteroids or fluoroquinolones. Prolonged use may increase the risk of ocular hypertension, cataract formation, or secondary ocular infections. Regular monitoring of intraocular pressure is recommended during therapy. Kitmox-LD Ophthalmic Suspension offers an effective therapeutic option for managing inflammatory ocular conditions complicated by bacterial infection.